More about

Venous Thromboembolism

News
January 15, 2020
2 min read
Save

Long-term risk for VTE significant after HF hospitalization

Long-term risk for VTE significant after HF hospitalization

Patients hospitalized for HF were found to have significantly elevated long-term risk for venous thromboembolism, regardless of ejection fraction.

News
January 10, 2020
1 min read
Save

Intestinal ultrasound monitors therapeutic response in IBD, inpatient opioids tied to future use — top stories in gastroenterology

Intestinal ultrasound monitors therapeutic response in IBD, inpatient opioids tied to future use — top stories in gastroenterology

Researchers found that using an intestinal ultrasound to assess bowel wall thickness can help monitor treatment response in patients with ulcerative colitis. This was one of the top stories in gastroenterology last week.

News
January 03, 2020
1 min read
Save

Early VTE linked with worse survival in pancreatic ductal adenocarcinoma

Frequent and early onset of venous thromboembolism are associated with decreased progression-free survival and overall survival among patients diagnosed with pancreatic ductal adenocarcinoma, according to study results.

News
December 30, 2019
2 min read
Save

Black patients at higher risk for cancer-associated venous thromboembolism

Black patients with cancer appeared to be at a higher risk for cancer-associated venous thromboembolism than patients of other races, according to results of a retrospective study published in American Journal of Clinical Oncology.

News
December 23, 2019
9 min watch
Save

VIDEO: Efgartigimod safe, effective in primary immune thrombocytopenia

VIDEO: Efgartigimod safe, effective in primary immune thrombocytopenia

ORLANDO — A 3-week treatment cycle of efgartigimod, a neonatal Fc receptor antagonist, was well tolerated and effective in patients with primary immune thrombocytopenia, according to phase 2 data presented at the ASH Annual Meeting and Exposition.

News
December 20, 2019
4 min watch
Save

VIDEO: Apixaban demonstrates benefit over other anticoagulation treatments

VIDEO: Apixaban demonstrates benefit over other anticoagulation treatments

ORLANDO — Apixaban reduced the risk for recurrent venous thromboembolism compared with low-molecular-weight heparin and warfarin, according to results of a large epidemiology study presented at the ASH Annual Meeting and Exposition.

News
December 20, 2019
2 min read
Save

Revision TJA alone not linked with higher VTE, wound drainage rates

Revision TJA alone not linked with higher VTE, wound drainage rates

There was no difference in venous thromboembolism and wound drainage rates in a comparison of chemoprophylactic agents used in low-risk patients who underwent revision compared with primary total joint arthroplasty, according to study results.

News
December 20, 2019
3 min watch
Save

VIDEO: Aspirin linked to bleeding events in patients receiving direct oral anticoagulants

VIDEO: Aspirin linked to bleeding events in patients receiving direct oral anticoagulants

ORLANDO — In this video at the ASH Annual Meeting and Exposition, Thein H. Oo, MD, FRCPE, FACP, reviews a study that showed the addition of aspirin to direct oral anticoagulants for venous thromboembolism or non-valvular atrial fibrillation was linked to an increase in bleeding events.

News
December 13, 2019
1 min read
Save

Tranexamic acid seen as effective blood conservation strategy in TJA

Tranexamic acid seen as effective blood conservation strategy in TJA

ORLANDO — Tranexamic acid is an efficacious and economical strategy to reduce bleeding among patients who undergo total joint arthroplasty, a presenter at the Current Concepts in Joint Replacement Winter Meeting said, here.

News
December 08, 2019
4 min read
Save

Tailored rivaroxaban regimens safe, effective for children with venous thromboembolism

Tailored rivaroxaban regimens safe, effective for children with venous thromboembolism

ORLANDO — Body weight-adjusted regimens of rivaroxaban appeared to be safe and effective for children with venous thromboembolism, according to results of a dose-exposure-response evaluation of the phase 3 EINSTEIN-Jr. study presented at ASH Annual Meeting and Exposition.

View more